Gilead Sciences Inc.: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-07-05
Other years: 2026 vs 2025
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

0
New Risks
2
Removed
10
Modified
12
Unchanged
🔴 No Match in Current Filing We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners. 🔒
🟡 Modified We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the healthcare industry. 🔒
🟡 Modified We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, or we may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners, which could limit our ability to generate revenues. 🔒
🔴 No Match in Current Filing We are subject to risks if significant safety issues arise for our marketed products or our product candidates. 🔒
🟡 Modified Our aspirations, goals and disclosures related to corporate responsibility matters expose us to numerous risks, including risks to our reputation and stock price. 🔒
🟡 Modified Climate change and natural disasters, as well as legal, regulatory, or market measures to address climate change, can negatively affect our business and operations. 🔒
🟡 Modified Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance, including if significant safety issues arise for our marketed products or our product candidates, could delay or halt commercialization of our products. 🔒
🟡 Modified We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption. 🔒
🟡 Modified Our success depends on developing and commercializing new products or expanding the indications for existing products. 🔒
🟡 Modified We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories. 🔒
🟡 Modified Certain of our products subject us to additional or heightened risks. 🔒
🟡 Modified We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions. 🔒
12 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →